AstraZeneca’s Covid-19 vaccine data fails to impress some experts
Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.
AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fuelled concerns about whether it can match competitors.
A sign is pictured outside the AstraZeneca factory in Liverpool north west England. (AFP)
Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc. “In the competitive context they fail to impress,” Gal wrote.
{{^htLoading}} {{/htLoading}}
{{^htLoading}}
Advertisement
{{/htLoading}}
Exacerbating concerns, the Lancet medical journal publication came just an hour after Pfizer and BioNtech had announced early positive data from their Covid-19 vaccine trial in Germany, which builds upon promising results from their program earlier this month.
US listed shares of AstraZeneca fell as much as 5.7% -- the biggest intraday decline since March -- bringing the stock’s year-to-date gain to 19%. Moderna, which is among biotech’s hottest stocks, was also down as much as 18% as JPMorgan downgraded its rating to the equivalent of a hold. AstraZeneca data “fail to impress” in a competitive context, “the titers from immunized patients were lower than convalescent patients, whereas BioNtech and Moderna vaccines both elicited IgGs substantially higher than convalescent controls,” said Bernstein, Ronny Gal.
Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.
Get the latest World News, breaking headlines, and real-time coverage from key global hotspots, including the US News, Russia, Ukraine, Iran News, and the UAE News. Track developing conflicts, high-stakes diplomacy, and major international events on Hindustan Times.
Get the latest World News, breaking headlines, and real-time coverage from key global hotspots, including the US News, Russia, Ukraine, Iran News, and the UAE News. Track developing conflicts, high-stakes diplomacy, and major international events on Hindustan Times.